

CITATION REPORT

List of articles citing

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer

DOI: 10.1016/j.pharmthera.2015.02.004

Pharmacology & Therapeutics, 2015, 151, 16-31.

Source: <https://exaly.com/paper-pdf/61773434/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
182	Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma. 2015 , 28, 718-29		43
181	NAMPT as a Therapeutic Target against Stroke. 2015 , 36, 891-905		55
180	Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT. 2015 , 5, 12657		15
179	Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression. 2015 , 36, 7859-63		32
178	Comparative Metabolomic Profiling Reveals That Dysregulated Glycolysis Stemming from Lack of Salvage NAD ⁺ Biosynthesis Impairs Reproductive Development in <i>Caenorhabditis elegans</i> . <i>Journal of Biological Chemistry</i> , 2015 , 290, 26163-79	5.4	16
177	Identification of a novel NAMPT inhibitor by combinatorial click chemistry and chemical refinement. 2015 , 6, 1891-1897		6
176	Research into cancer metabolomics: Towards a clinical metamorphosis. 2015 , 43, 52-64		31
175	Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. <i>Oncotarget</i> , 2016 , 7, 2968-84	3.3	41
174	Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway. 2016 , 2016, 1450843		33
173	Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke. 2016 , 22, 782-8		27
172	Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases. 2016 , 119, 548-554		21
171	Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis. 2016 , 22, 431-9		16
170	NAMPT and NAMPT-controlled NAD Metabolism in Vascular Repair. 2016 , 67, 474-81		23
169	A Time for MYC: Metabolism and Therapy. 2016 , 81, 79-83		31
168	Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016 , 26, 2920-2926	2.9	7
167	First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib. 2016 , 11, 3179-3190		73
166	The metabolomic signature of hematologic malignancies. 2016 , 49, 22-35		14

165	Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine. 2016 , 173, 2182-94		60
164	Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF- κ B/IL-6 signals. 2016 , 791, 322-330		14
163	Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 8345-68	8.3	13
162	Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth. 2016 , 15, 2119-29		73
161	Issue Investigation and Practices in Discovery Toxicology. 2016 , 530-539		
160	Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis. 2016 , 91, 709-13		4
159	Anti-Inflammation Effects and Potential Mechanism of Saikosaponins by Regulating Nicotinate and Nicotinamide Metabolism and Arachidonic Acid Metabolism. 2016 , 39, 1453-61		45
158	Solvation State of Nicotinamide in Binary Solvents by ¹³ C NMR Probing at Different Temperatures. 2016 , 47, 349-359		3
157	Nicotinamide phosphoribosyltransferase leukocyte overexpression in GravesRophthalmopathy. 2016 , 53, 497-504		11
156	Exploring NAD ⁺ metabolism in host-pathogen interactions. 2016 , 73, 1225-36		33
155	Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016 , 26, 765-768	2.9	11
154	Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways. 2016 , 101, 13-26		17
153	New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology. 2016 , 3, e1052180		31
152	Cancer metabolism: a therapeutic perspective. 2017 , 14, 11-31		659
151	Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension. 2017 , 135, 1532-1546		41
150	Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 1768-1792	8.3	30
149	Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors. 2017 , 16, 1236-1245		13
148	Metabolic regulation of suppressive myeloid cells in cancer. 2017 , 35, 27-35		23

147	SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017 , 27, 3317-3325	2.9	8
146	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in -Mutant Cancers and Potentiates NAD Depletion-Mediated Cytotoxicity. <i>Cancer Research</i> , 2017 , 77, 4102-4115	10.1	53
145	Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease. 2017 , 92, 922-933		7
144	Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. 2017 , 7, 603-621		51
143	Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma. 2017 , 38, 271-280		42
142	Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration. 2017 , 16, 2677-2688		19
141	Targeting metabolic pathways for head and neck cancers therapeutics. 2017 , 36, 503-514		23
140	NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma. 2017 , 15, 1714-1721		25
139	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 7965-7983	8.3	60
138	Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2017 , 23, 7301-7311 ^{12,9,31}		
137	Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD biosynthesis pathway and NAMPT mutation. <i>Biochemical and Biophysical Research Communications</i> , 2017 , 491, 681-686	3.4	20
136	Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1). 2017 , 80, 395-403		18
135	Adipocytokines, Energy Balance, and Cancer. 2017 ,		1
134	Visfatin, Obesity, and Cancer. 2017 , 109-136		6
133	Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells. 2017 , 16, 191		13
132	NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis. <i>Oncotarget</i> , 2017 , 8, 99514-99530	3.3	39
131	Parahydrogen-Based Hyperpolarization for Biomedicine. 2018 , 57, 11140-11162		170
130	Identification of the Nicotinamide Salvage Pathway as a New Toxication Route for Antimetabolites. 2018 , 25, 471-482.e7		40

129	The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges. 2018 , 82, 72-87		41
128	NAMPT-mediated NAD biosynthesis is indispensable for adipose tissue plasticity and development of obesity. 2018 , 11, 178-188		39
127	Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. 2018 , 110,		27
126	From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish. 2018 , 161, 300-309		12
125	Targeting the vulnerability to NAD depletion in B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018 , 32, 616-625	10.7	22
124	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery. 2018 , 9, 34-38		28
123	Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy. 2018 , 28, 201-212		65
122	Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment. <i>Oncotarget</i> , 2018 , 9, 16451-16461	3.3	14
121	Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug Conjugates. 2018 , 17, 2633-2642		14
120	Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets. 2018 , 131, 102-109		38
119	Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies. 2018 , 2018, 1316390		4
118	Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. 2018 , 155, 799-814.e13		46
117	Genotype-targeted local therapy of glioma. 2018 , 115, E8388-E8394		29
116	NAMPT: A pleiotropic modulator of monocytes and macrophages. 2018 , 135, 25-36		37
115	Parawasserstoff-basierte Hyperpolarisierung für die Biomedizin. 2018 , 130, 11310-11333		45
114	5-Hydroxymethyltetrahydropteridine diphosphate (5-HMP) production in Escherichia coli. 2018 , 8, 12278		11
113	Identification of potent triazolopyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. <i>European Journal of Medicinal Chemistry</i> , 2019 , 181, 111576 ^{6.8}		5
112	Multi-dimensional immunoproteomics coupled with in vitro recapitulation of oncogenic NRAS identifies diagnostically relevant autoantibody biomarkers in thyroid neoplasia. <i>Cancer Letters</i> , 2019 , 467, 96-106	9.9	6

111	Knockdown of estrogen receptor \bar{u} increases proliferation and affects the transcriptome of endometrial adenocarcinoma cells. <i>BMC Cancer</i> , 2019 , 19, 745	4.8	5
110	The Role of Adipose Tissue in the Pathogenesis and Therapeutic Outcomes of Inflammatory Bowel Disease. <i>Cells</i> , 2019 , 8,	7.9	23
109	High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor. 2019 , 865, 172738		12
108	Scaffold Morphing Identifies 3-Pyridyl Azetidine Ureas as Inhibitors of Nicotinamide Phosphoribosyltransferase (NAMPT). 2019 , 10, 1524-1529		4
107	Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin. <i>BMC Cancer</i> , 2019 , 19, 1027	4.8	16
106	NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 736	5.3	13
105	Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance. <i>Cancers</i> , 2019 , 11,	6.6	48
104	Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis. 2019 , 21, 974-988		5
103	PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. 2019 , 10, 3790		26
102	Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening. 2019 , 9, 7742		2
101	Structure-based drug design of novel carborane-containing nicotinamide phosphoribosyltransferase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019 , 27, 2832-2844	3.4	8
100	Inflammatory macrophage dependence on NAD salvage is a consequence of reactive oxygen species-mediated DNA damage. 2019 , 20, 420-432		90
99	Subcellular compartmentalization of NAD and its role in cancer: A sereneNAde of metabolic melodies. <i>Pharmacology & Therapeutics</i> , 2019 , 200, 27-41	13.9	30
98	Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. 2019 , 3, 242-255		23
97	Utilization of F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo. 2019 , 371, 583-589		1
96	Proteomic identification of a marker signature for MAPKi resistance in melanoma. 2019 , 38, e95874		11
95	Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells. 2019 , 39, 6457-6462		4
94	Targeting NAD Metabolism to Enhance Radiation Therapy Responses. 2019 , 29, 6-15		15

93	Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells. 2019 , 111, 1889-1895		8
92	The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target. 2018 , 36, 5		12
91	Non-thermal plasma-activated medium modified metabolomic profiles in the glycolysis of U251SP glioblastoma. 2019 , 662, 83-92		21
90	Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic. 2019 , 2, e1131		7
89	Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. 2019 , 49, 1063-1077		1
88	Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT). 2020 , 98, 192-201		20
87	Epigenetic polypharmacology: A new frontier for epi-drug discovery. 2020 , 40, 190-244		49
86	Role of coenzymes in cancer metabolism. 2020 , 98, 44-53		12
85	KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells. 2020 , 33, 482-491		8
84	NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer. <i>Cancer Research</i> , 2020 , 80, 890-900	10.1	34
83	Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2020 , 34, 1524-1539	10.7	9
82	Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening. <i>Bioorganic and Medicinal Chemistry</i> , 2020 , 28, 115217	3.4	1
81	OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. <i>Leukemia</i> , 2020 , 34, 1828-1839	10.7	13
80	Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. <i>Molecules</i> , 2020 , 25,	4.8	10
79	Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. <i>Cell Stem Cell</i> , 2020 , 27, 748-764.e4	18	43
78	Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors. <i>Molecules</i> , 2020 , 25,	4.8	3
77	Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target. <i>EBioMedicine</i> , 2020 , 61, 103059	8.8	13
76	Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma. <i>Oncogenesis</i> , 2020 , 9, 80	6.6	6

75	NAD Metabolism and Regulation: Lessons From Yeast. <i>Biomolecules</i> , 2020 , 10,	5.9	12
74	Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy. <i>Frontiers in Oncology</i> , 2019 , 9, 1514	5.3	34
73	An RNA-binding-protein, NONO governs energy metabolism by regulating NAMPT in lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 528, 376-382	3.4	3
72	NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview. <i>Biomolecules</i> , 2020 , 10,	5.9	19
71	Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity. <i>Leukemia</i> , 2020 , 34, 1885-1897	10.7	9
70	NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation. <i>Frontiers in Oncology</i> , 2020 , 10, 358	5.3	46
69	Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential. <i>Cancer Letters</i> , 2021 , 498, 229-239	9.9	13
68	Sirtuin activation targets IDH-mutant tumors. <i>Neuro-Oncology</i> , 2021 , 23, 53-62	1	8
67	Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer. <i>European Journal of Medicinal Chemistry</i> , 2021 , 211, 113022	6.8	3
66	NAD+: a crucial regulator of sirtuin activity in aging. 2021 , 23-35		
65	Mono(ADP-ribosyl)ation Enzymes and NAD Metabolism: A Focus on Diseases and Therapeutic Perspectives. <i>Cells</i> , 2021 , 10,	7.9	5
64	NAMPT promotes hepatitis B virus replication and liver cancer cell proliferation through the regulation of aerobic glycolysis. <i>Oncology Letters</i> , 2021 , 21, 390	2.6	2
63	Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening. <i>PLoS ONE</i> , 2021 , 16, e0248140	3.7	3
62	Visfatin facilitates gastric cancer malignancy by targeting snai1 via the NF- κ B signaling. <i>Human and Experimental Toxicology</i> , 2021 , 40, 1646-1655	3.4	0
61	NMNAT promotes glioma growth through regulating post-translational modifications of p53 to inhibit apoptosis.		
60	NAD Metabolism, Metabolic Stress, and Infection. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 686412	5.6	4
59	Advances in NAD-Lowering Agents for Cancer Treatment. <i>Nutrients</i> , 2021 , 13,	6.7	7
58	Small Molecule Regulators Targeting NAD ⁺ Biosynthetic Enzymes. <i>Current Medicinal Chemistry</i> , 2021 ,	4.3	0

57	Optimization of a urea-containing series of nicotinamide phosphoribosyltransferase (NAMPT) activators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021 , 41, 128007	2.9	3
56	Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 101	22.4	2
55	Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
54	A circular RNAs dataset landscape reveals potential signatures for the detection and prognosis of early-stage lung adenocarcinoma. <i>BMC Cancer</i> , 2021 , 21, 781	4.8	3
53	The Extracellular NADome Modulates Immune Responses. <i>Frontiers in Immunology</i> , 2021 , 12, 704779	8.4	5
52	Meta-transcriptomic profiling of functional variation of freshwater microbial communities induced by an antidepressant sertraline hydrochloride. <i>Science of the Total Environment</i> , 2021 , 786, 147434	10.2	1
51	Antioxidant responses related to temozolomide resistance in glioblastoma. <i>Neurochemistry International</i> , 2021 , 149, 105136	4.4	2
50	Genotoxic therapy and resistance mechanism in gliomas. <i>Pharmacology & Therapeutics</i> , 2021 , 228, 107923	23.9	11
49	The nicotinamide phosphoribosyltransferase antagonist FK866 inhibits growth of prostate tumour spheroids and increases doxorubicin retention without changes in drug transporter and cancer stem cell protein expression. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021 , 48, 422-434	3	4
48	Local Targeting of NAD Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma. <i>Cancer Research</i> , 2020 , 80, 5024-5034	10.1	8
47	Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP. <i>Clinical Cancer Research</i> , 2018 , 24, 1202-1215	12.9	69
46	Nicotinamide metabolism regulates glioblastoma stem cell maintenance. <i>JCI Insight</i> , 2017 , 2,	9.9	51
45	Up-regulation of miR-381 inhibits NAD ⁺ salvage pathway and promotes apoptosis in breast cancer cells. <i>EXCLI Journal</i> , 2019 , 18, 683-696	2.4	11
44	High-throughput proteomics integrated with gene microarray for discovery of colorectal cancer potential biomarkers. <i>Oncotarget</i> , 2016 , 7, 75279-75292	3.3	24
43	Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression. <i>Oncotarget</i> , 2017 , 8, 14374-14394	3.3	7
42	EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. <i>Oncotarget</i> , 2017 , 8, 24679-24693	3.3	18
41	Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma. <i>Oncotarget</i> , 2018 , 9, 18997-19005	3.3	18
40	Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism. <i>Oncotarget</i> , 2016 , 7, 32306-17	3.3	20

39	Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2019 , 7, 785	3.2	8
38	Recent Advances in NAMPT Inhibitors: A Novel Immunotherapeutic Strategy. <i>Frontiers in Pharmacology</i> , 2020 , 11, 656	5.6	36
37	Aging, geroprotectors, gene therapy. <i>Regional Ecology</i> , 2019 , 56, 109	0.3	
36	Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients. <i>Aging</i> , 2020 , 12, 16457-16475	5.6	0
35	High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients. <i>American Journal of Cancer Research</i> , 2015 , 5, 2447-54	4.4	6
34	NMNAT promotes glioma growth through regulating post-translational modifications of P53 to inhibit apoptosis.. <i>ELife</i> , 2021 , 10,	8.9	1
33	Thromboinflammatory Processes at the Nexus of Metabolic Dysfunction and Prostate Cancer: The Emerging Role of Periprostatic Adipose Tissue.. <i>Cancers</i> , 2022 , 14,	6.6	0
32	Proteomic analysis reveals microvesicles containing NAMPT as mediators of radiation resistance in glioma.		
31	NAMPT: A critical driver and therapeutic target for cancer.. <i>International Journal of Biochemistry and Cell Biology</i> , 2022 , 145, 106189	5.6	3
30	PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.. <i>Cancers</i> , 2021 , 14,	6.6	0
29	Image_1.TIF. 2019 ,		
28	Image_2.TIF. 2019 ,		
27	Table_1.DOC. 2019 ,		
26	Fueling genome maintenance: On the versatile roles of NAD ⁺ in preserving DNA integrity. <i>Journal of Biological Chemistry</i> , 2022 , 102037	5.4	1
25	Ispinesib as an Effective Warhead for the Design of Autophagosome-Tethering Chimeras: Discovery of Potent Degradors of Nicotinamide Phosphoribosyltransferase (NAMPT).. <i>Journal of Medicinal Chemistry</i> , 2022 ,	8.3	6
24	Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer. <i>Journal of Medicinal Chemistry</i> ,	8.3	1
23	Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5787	6.3	0
22	A Novel NAMPT Inhibitor-Based AntibodyDrug Conjugate Payload Class for Cancer Therapy. <i>Bioconjugate Chemistry</i> ,	6.3	2

21	Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer. <i>European Journal of Medicinal Chemistry</i> , 2022 , 114504	6.8	1
20	Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors. <i>Pharmaceuticals</i> , 2022 , 15, 855	5.2	2
19	From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases. <i>Frontiers in Pharmacology</i> , 13,	5.6	
18	MicroRNA-26b Reduces Cell Viability by Inhibition of Nicotinamide Phosphoribosyltransferase in Breast Cancer Cells. <i>DNA and Cell Biology</i> ,	3.6	0
17	Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment. 2022 , 22,		
16	Bourgeoning Cancer Targets. 2022 , 17,		1
15	Adipose tissue-to-breast cancer crosstalk: Comprehensive insights. 2022 , 1877, 188800		0
14	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. 2022 , 23, 9985		2
13	Review of various NAMPT inhibitors for the treatment of cancer. 13,		3
12	Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT. 2022 , 65, 15725-15737		1
11	Synthesis and Evaluation of Reactive Oxygen Species Sensitive Prodrugs of a NAMPT Inhibitor FK866. 2023 , 28, 169		0
10	Immunohistochemical Analysis of Nicotinamide Phosphoribosyltransferase Expression in Gastric and Esophageal Adenocarcinoma (AEG). 2022 , 4, 333-340		0
9	Targeting of Glucose Transport and the NAD Pathway in Neuroendocrine Tumor (NET) Cells Reveals New Treatment Options. 2023 , 15, 1415		0
8	Inducible mismatch repair streamlines forward genetic approaches to target identification of cytotoxic small molecules.		0
7	Screening in serum-derived medium reveals differential response to compounds targeting metabolism.		0
6	Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer. 2023 , 13,		0
5	Novel carbon skeletons activate human NicotinAMide Phosphoribosyl Transferase (NAMPT) enzyme in biochemical assay. 2023 , 18, e0283428		0
4	Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment.		0

- 3 Construction of a prognostic model for gastric cancer patients based on NAD⁺ metabolism-related genes and tumor microenvironment analysis. ○
- 2 Proteomic analysis reveals microvesicles containing NAMPT as mediators of radioresistance in glioma. **2023**, 6, e202201680 ○
- 1 Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia. ○